Gilead
AbbVie hep C treatment fast-tracked
June 18, 2014Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi
The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …
NICE rejection looms for Sovaldi
June 16, 2014Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi
In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …
Sovaldi hurdles first drug pricing barrier
June 10, 2014Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi
Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …
Sales forecasts leave Sovaldi top and Januvia lagging
May 23, 2014Sales and Marketing Gilead, Januvia, Merck, diabetes, ep, hep C, sovaldi
Sovaldi has topped analysts’ estimates for future growth but Merck’s big-selling diabetes drug Januvia is falling by the wayside. This …
Gilead price lambasted by US health insurers
May 21, 2014Medical Communications, Sales and Marketing Gilead, Incivek, Victrelis, hepatitis C, sovaldi
Gilead’s new hepatitis C pill Sovaldi is coming under more pressure in the US as health insurers hit out at …
Sovaldi performs for Gilead
April 24, 2014Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …
Novartis sues Biocon
April 4, 2014Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir
India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …
CHMP breathes new life into GSK, Teva and Novartis
February 24, 2014Research and Development, Sales and Marketing CHMP, COPD, EMA, GSK, Gilead, Teva, asthma, onoro
The CHMP has given its backing to a number of new treatments for respiratory diseases, which include two from London-based …
‘Compassionate’ use of hep C combo
February 24, 2014Research and Development, Sales and Marketing CHMP, EMA, Gilead, hep C, ledipasvir, sovaldi
A key adviser to the European regulator has said that Gilead Sciences’ fixed-dose combination of Sovaldi and ledipasvir can be …
Pharma’s reputation ‘getting worse’
February 17, 2014Medical Communications, Sales and Marketing GSK, Gilead, Pfizer, ViiV, patientview, pharma, reputation
The pharma industry’s reputation is getting worse – at least, in the eyes of 800 patient groups – according to …
Gilead to allow cheaper generics of new hep C drug
February 6, 2014Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi
Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …
Europe nod for Gilead HCV pill
January 20, 2014Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …
AbbVie posts strong results for Hep C pill
December 11, 2013Research and Development, Sales and Marketing 3D, AbbVie, FDA, Gilead, hep C
AbbVie’s investigational hepatitis C pill cured 96% of difficult-to-treat patients in a late-stage clinical trial and looks set to muscle …
Gilead’s $1,000 per day Hep C drug approved
December 9, 2013Sales and Marketing FDA, Gilead, hepc, sofosbuvir, sovaldi
Gilead’s Sovaldi has gained FDA approval as a potential cure for hepatitis C after the US regulator sped up its …
Gilead runs into India patent trouble
November 26, 2013Sales and Marketing Gilead, MSF, hepc, sofosbuvir, sovaldi
Gilead Sciences has run into heavy traffic in India as campaigners attempt to block the company’s patent there on new …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
